Clinical Trial Update: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing durvalumab and tremelimumab versus doxorubicin in advanced/metastatic soft tissue sarcoma (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED